Astrazeneca Pharma India Ltd Stock Analysis

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price Jan 17, 12:59
3026.00 -39.00 (-1.27%)

DeciZen - Make an Informed Decision on Astrazeneca Pharma I

Overall Rating

1. Quality

2. Valuation

Overvalued
P/E P/S EV/EBITDA

3. Price Trend

10 Year X-Ray:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
ROCE % 10.6%-65.4%-9.6%-13%3.6%10.8%11.1%19.7%22%22.7%-
Value Creation Index -0.3-5.7-1.7-1.9-0.8-0.2-0.20.40.60.7-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 531390474517564544571728832814784
YoY Gr. Rt. %--26.5%21.4%9.1%9%-3.6%5%27.6%14.2%-2.2%-
Adj EPS 7.8-37.8-5.2-8.42.28.210.521.628.936.928.2
YoY Gr. Rt. %--585.9%NANANA274.3%28.1%106.5%34.1%27.4%-
BVPS (₹) 75.739.968.660.362.488.597.9119.5145.1181.8189.2
Adj Net Profit 19.5-94.5-13-215.520.426.15472.392.271
Cash Flow from Ops. 38.7-6-0.8-45.75738.18.85587.4105-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales 4.9%7.6%12.5%-2.2%
Adj EPS 18.9%76%52.2%27.4%
BVPS 10.223.922.925.3
Share Price 6.9% 25.8% 22.8% -28.3%

Key Financial Parameters

Performance Ratio Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity % 10.6-65.4-9.6-133.610.811.119.721.722.515.2
Op. Profit Mgn % 5.8-17.5-2.7-2.236.98.29.814.616.713.4
Net Profit Mgn % 3.7-24.2-2.8-4.113.84.67.48.711.39
Debt to Equity 00000000000
Working Cap Days 117171155173167185216177168194298
Cash Conv. Cycle 555117111711120-20149

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 12.53%

Net Profit is growing at healthy rate in last 3 years 52.22%

Return on Equity has declined versus last 3 years average to 15.20%

Sales growth is not so good in last 4 quarters at -4.42%

Latest Financials - Astrazeneca Pharma India Ltd.

Standalone Consolidated
TTM EPS (₹) 28.2 -
TTM Sales (₹ Cr.) 784 -
BVPS (₹.) 189.2 -
Reserves (₹ Cr.) 468 -
P/BV 16.20 -
PE 108.66 -
From the Market
52 Week Low / High (₹) 2930.00 / 4580.00
All Time Low / High (₹) 9.00 / 4970.00
Market Cap (₹ Cr.) 7,663
Equity (₹ Cr.) 5
Face Value (₹) 2
Industry PE 41.2

Management X-Ray:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes

News

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
Read More Read Less